Repeated haloperidol increases both calmodulin and a calmodulin-binding protein in rat striatum
dc.contributor.author | Gnegy, Margaret E. | en_US |
dc.contributor.author | Agrawal, Alka | en_US |
dc.contributor.author | Hewlett, Keiki | en_US |
dc.contributor.author | Yeung, Evan | en_US |
dc.contributor.author | Yee, Susan L. | en_US |
dc.date.accessioned | 2006-04-10T17:42:54Z | |
dc.date.available | 2006-04-10T17:42:54Z | |
dc.date.issued | 1994-12 | en_US |
dc.identifier.citation | Gnegy, Margaret E., Agrawal, Alka, Hewlett, Keiki, Yeung, Evan, Yee, Susan (1994/12)."Repeated haloperidol increases both calmodulin and a calmodulin-binding protein in rat striatum." Molecular Brain Research 27(2): 195-204. <http://hdl.handle.net/2027.42/31144> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T07-4859R4F-1/2/67948ce78fa26db686b5b5640ab03ce8 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/31144 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7898303&dopt=citation | en_US |
dc.description.abstract | Repeated treatment with the antipsychotic drug, haloperidol, leads to an increased behavioral sensitivity to dopamine agonists exhibited upon withdrawal from the drug. An increase in the particulate content of the endogenous Ca2+-binding protein, calmodulin, has been demonstrated after repeated treatment of rats with haloperidol. In this study, the anatomical specificity of the effect of repeated haloperidol treatment on the content and subcellular localization of calmodulin was investigated. Responsivity of calmodulin localization to dopaminergic input following drug treatment was assessed by determining the subcellular localization of calmodulin following an in vivo amphetamine challenge before sacrifice. Male, Sprague-Dawley rats were treated with 0.5 mg/kg haloperidol (s.c.) for 3 weeks and withdrawn from the drug for 4 days. Repeated haloperidol increased calmodulin content only in the striatum but altered the subcellular distribution of calmodulin in rat limbic forebrain and frontal cortex. In the latter areas, the soluble calmodulin was increased while the particulate calmodulin was decreased. There was no change in calmodulin in either hippocampus or cerebellum in response to drug treatment. Challenge with the dopamine mimetic, amphetamine, before sacrifice was effective in redistributing calmodulin only in striatum from rats that had been treated repeatedly with haloperidol, demonstrating an increased sensitivity of the translocation process. In order to determine whether a change in a calmodulin-binding protein would accompany the drug-induced increase in calmodulin, striatal calmodulin-binding proteins were examined using a biotinylated calmodulin overlay technique. Repeated haloperidol treatment enhanced calmodulin binding to a 150 kDa protein in striatal membranes. The 150 kDa protein exhibited the same gel mobility and subcellular distribution as myosin light chain kinase immunoreactivity. There was an increase in myosin light chain kinase immunoreactivity in striatal membranes after repeated haloperidol that was apparent in animals withdrawn either 4 or 10 days from haloperidol treatment. Therefore, repeated haloperidol could increase the rat striatal content of calmodulin and potentially that of the calmodulin-binding protein, myosin light chain kinase. Increases in striatal calmodulin and myosin light chain kinase may signal a greatly enhanced sensitivity of actin-myosin interactions after repeated haloperidol that could contribute to haloperidol-induced neurochemical or morphological changes involved in drug-induced synaptic plasticity. | en_US |
dc.format.extent | 1131800 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Repeated haloperidol increases both calmodulin and a calmodulin-binding protein in rat striatum | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Psychology | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Social Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmacology, 7427 Medical Sciences I, University of Michigan Medical School, Ann Arbor, MI 48103-0626, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacology, 7427 Medical Sciences I, University of Michigan Medical School, Ann Arbor, MI 48103-0626, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacology, 7427 Medical Sciences I, University of Michigan Medical School, Ann Arbor, MI 48103-0626, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacology, 7427 Medical Sciences I, University of Michigan Medical School, Ann Arbor, MI 48103-0626, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacology, 7427 Medical Sciences I, University of Michigan Medical School, Ann Arbor, MI 48103-0626, USA | en_US |
dc.identifier.pmid | 7898303 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/31144/1/0000041.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0169-328X(94)90001-9 | en_US |
dc.identifier.source | Molecular Brain Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.